Solid Biosciences Inc. SLDB Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Underwriting Discounts And Commissions
Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Underwriting Discounts And Commissions at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept sldb:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfUnderwritingDiscountsAndCommissions.
The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solid Biosciences Inc.'s proceeds from issuance of common stock and pre funded warrants in public offering net of underwriting discounts and commissions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solid Biosciences Inc.'s proceeds from issuance of common stock and pre funded warrants in public offering net of underwriting discounts and commissions?
- Solid Biosciences Inc. (SLDB) reported proceeds from issuance of common stock and pre funded warrants in public offering net of underwriting discounts and commissions of $0 in Q1 2026.
- How has Solid Biosciences Inc.'s proceeds from issuance of common stock and pre funded warrants in public offering net of underwriting discounts and commissions changed year-over-year?
- Solid Biosciences Inc.'s proceeds from issuance of common stock and pre funded warrants in public offering net of underwriting discounts and commissions decreased by 100.0% year-over-year, from $189.64M to $0.
- What does proceeds from issuance of common stock and pre funded warrants in public offering net of underwriting discounts and commissions mean?
- This measures the total cash inflows generated from public equity offerings, including common stock and pre-funded warrants, net of underwriting fees. It serves as a primary indicator of the company's ability to access capital markets to fund R&D and operational runway. High proceeds indicate strong investor demand and successful capital raising efforts.